Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

NCT04510298 is registered in ClinicalTrials.gov with Sirtsei Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04510298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2020
Completion date
April 15, 2021
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia